Envoy Medical Ends $15M ATM Equity Facility Effective June 24, 2026
COCH•Envoy Medical terminated its at-the-market equity facility that authorized up to $15 million of common stock sales, effective June 24, 2026. The company cited confidence in its current capital reserves and will no longer access the ATM program to fund operations.
1. ATM Equity Facility Terminated
Envoy Medical formally ended its at-the-market equity facility on June 24, 2026, eliminating its ability to sell up to $15 million of common stock under that program. No further share offerings will be conducted through this mechanism.
2. Financial Strength Signal
The termination reflects management’s stated confidence in existing liquidity and operating cash flow, reducing reliance on equity sales. Investors may view this move as a signal of sufficient capital to support ongoing operations without dilution.
3. Company Overview
Envoy Medical develops fully implanted hearing solutions, including the FDA-approved Esteem active middle ear implant and the investigational Acclaim cochlear implant. The company focuses on advancing hearing technology to address moderate to profound sensorineural hearing loss.
